Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma.

Publication ,  Journal Article
Sarver, M; Brown, MC; Rhodin, KE; Salama, AKS; Beasley, GM
Published in: Hum Vaccin Immunother
May 31, 2022

This review describes the current body of literature and ongoing clinical trials examining neoadjuvant immune checkpoint inhibitors (ICI) for patients with resectable stage III and IV melanoma. Based on prior success in treating metastatic melanoma and as adjuvant therapy, ICIs are being explored in the neoadjuvant setting. There have been initial trials and there are many ongoing trials examining neoadjuvant ICI. Herein, we will review the clinical feasibility and efficacy of various neoadjuvant ICI regimens, explore pathologic and cellular responses, and present factors associated with predictive tumor response.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Hum Vaccin Immunother

DOI

EISSN

2164-554X

Publication Date

May 31, 2022

Volume

18

Issue

3

Start / End Page

1943987

Location

United States

Related Subject Headings

  • Virology
  • Neoadjuvant Therapy
  • Melanoma
  • Immune Checkpoint Inhibitors
  • Humans
  • Combined Modality Therapy
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1108 Medical Microbiology
  • 1107 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sarver, M., Brown, M. C., Rhodin, K. E., Salama, A. K. S., & Beasley, G. M. (2022). Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. Hum Vaccin Immunother, 18(3), 1943987. https://doi.org/10.1080/21645515.2021.1943987
Sarver, Melissa, Michael C. Brown, Kristen E. Rhodin, April K. S. Salama, and Georgia M. Beasley. “Predictive factors of neoadjuvant immune checkpoint blockade in melanoma.Hum Vaccin Immunother 18, no. 3 (May 31, 2022): 1943987. https://doi.org/10.1080/21645515.2021.1943987.
Sarver M, Brown MC, Rhodin KE, Salama AKS, Beasley GM. Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. Hum Vaccin Immunother. 2022 May 31;18(3):1943987.
Sarver, Melissa, et al. “Predictive factors of neoadjuvant immune checkpoint blockade in melanoma.Hum Vaccin Immunother, vol. 18, no. 3, May 2022, p. 1943987. Pubmed, doi:10.1080/21645515.2021.1943987.
Sarver M, Brown MC, Rhodin KE, Salama AKS, Beasley GM. Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. Hum Vaccin Immunother. 2022 May 31;18(3):1943987.

Published In

Hum Vaccin Immunother

DOI

EISSN

2164-554X

Publication Date

May 31, 2022

Volume

18

Issue

3

Start / End Page

1943987

Location

United States

Related Subject Headings

  • Virology
  • Neoadjuvant Therapy
  • Melanoma
  • Immune Checkpoint Inhibitors
  • Humans
  • Combined Modality Therapy
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1108 Medical Microbiology
  • 1107 Immunology